<?xml version="1.0" encoding="utf-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"><url><loc>https://www.yirui-pharma.com/</loc></url><url><loc>https://www.yirui-pharma.com/management</loc></url><url><loc>https://www.yirui-pharma.com/pipelines-and-partners</loc></url><url><loc>https://www.yirui-pharma.com/contact</loc></url><url><loc>https://www.yirui-pharma.com/hr</loc></url><url><loc>https://www.yirui-pharma.com/chinesehomepage</loc></url><url><loc>https://www.yirui-pharma.com/blog</loc></url><url><loc>https://www.yirui-pharma.com/blog/yr001-topical-ointment-china-bridging-study-completed-zh</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yr001-topical-ointment-china-bridging-study-completed</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yirui-pharma-series-a-plus-plus-financing-zh</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yirui-pharma-series-a-plus-plus-financing</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yr011-oral-tablet-china-ind-approval-zh</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yr011-oral-tablet-china-ind-approval</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yr011-oral-tablet-us-ind-approval-zh</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yr011-oral-tablet-us-ind-approval</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yr001-topical-ointment-us-phase-iia-primary-endpoint-zh</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yr001-topical-ointment-us-phase-iia-primary-endpoint</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yr001-topical-ointment-china-ind-approval-zh</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yr001-topical-ointment-china-ind-approval</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yirui-pharma-series-a-plus-financing-zh</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yirui-pharma-series-a-plus-financing</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yr001-topical-ointment-us-phase-i-completed-zh</loc><lastmod>2026-11-13</lastmod></url><url><loc>https://www.yirui-pharma.com/blog/yr001-topical-ointment-us-phase-i-completed</loc><lastmod>2026-11-13</lastmod></url></urlset>